Prostate-specific membrane antigen expression as a predictor of prostate cancer progression
Prostate-specific membrane antigen expression as a predictor of prostate cancer progression
复制标题
DOI：
10.1016/j.humpath.2006.11.012
复制
发表时间：
2007-05-01
期刊：
影响因子：
3.3
通讯作者：
Rubin, Mark A.
中科院分区：
文献类型：
--
作者：
Perner, Sven;Hofer, Matthias D.;Rubin, Mark A.
区分侵袭性前列腺癌与惰性疾病是一个重要的临床挑战，因为目前的治疗可能导致对有限疾病的男性过度治疗。前列腺特异性膜抗原（PSMA）是一种高度局限于前列腺的膜结合糖蛋白。以前，分析PSMA表达的研究发现了与前列腺癌相关的上调，特别是在晚期癌症中。这种关联对于作为预后标志物的应用是理想的。在目前的研究中，我们在一个高风险队列中描述了PSMA的表达，并评估了其作为前列腺特异性抗原（PSA）复发预测标志物的潜在用途。PSMA表达通过免疫组织化学使用由来自450名患者的肿瘤样品组成的组织微阵列进行分析。使用半自动定量显微镜系统（ACIS II; Clarient Chromavision Medical Systems，圣胡安Capistrano，CA）记录蛋白质强度。PSMA表达水平在前列腺外浸润（P = 0.017）、精囊浸润（P
Distinguishing aggressive prostate cancer from indolent disease represents an important clinical challenge, because current therapy may lead to overtreatment of men with limited disease. The prostate-specific membrane antigen (PSMA) is a membrane-bound glycoprotein that is highly restricted to the prostate. Previously, studies analyzing the expression of PSMA have found an up-regulation in correlation with prostate cancer, particularly in advanced cancer. This association is ideal for an application as a prognostic marker. In the current study, we characterized PSMA expression in a high-risk cohort and evaluated its potential use as predictive marker of prostate-specific antigen (PSA) recurrence. PSMA expression was analyzed by immunohistochemistry using tissue microarrays composed of tumor samples from 450 patients. Protein intensity was recorded using a semiautomated quantitative microscope system (ACIS II; Clarient Chromavision Medical Systems, San Juan Capistrano, CA). PSMA expression levels differed significantly (P 20%; P < .001), extraprostatic extension (P =.017), seminal vesicle invasion (P